224 related articles for article (PubMed ID: 38151613)
1. Copper Homeostasis Based on Cuproptosis-Related Signature Optimizes Molecular Subtyping and Treatment of Glioma.
Zhang S; Yu H; Sun S; Fan X; Bi W; Li S; Wang W; Fang Z; Chen X
Mol Neurobiol; 2023 Dec; ():. PubMed ID: 38151613
[TBL] [Abstract][Full Text] [Related]
2. The cuproptosis-related signature associated with the tumor environment and prognosis of patients with glioma.
Wang W; Lu Z; Wang M; Liu Z; Wu B; Yang C; Huan H; Gong P
Front Immunol; 2022; 13():998236. PubMed ID: 36110851
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas.
Bao JH; Lu WC; Duan H; Ye YQ; Li JB; Liao WT; Li YC; Sun YP
Front Immunol; 2022; 13():933973. PubMed ID: 36045691
[TBL] [Abstract][Full Text] [Related]
4. Identification and validation of a novel cuproptosis-related signature as a prognostic model for lung adenocarcinoma.
Chen Y; Tang L; Huang W; Zhang Y; Abisola FH; Li L
Front Endocrinol (Lausanne); 2022; 13():963220. PubMed ID: 36353226
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of cuproptosis-related genes signature and its impact on the reshaped immune microenvironment of glioma.
Chen S; Zhang S; Yuan Y; Wang Z; Li J; Li T; Zuo M; Feng W; Chen M; Liu Y
Front Pharmacol; 2022; 13():1016520. PubMed ID: 36267281
[TBL] [Abstract][Full Text] [Related]
6. A novel cuproptosis-related gene signature to predict prognosis in Glioma.
Zhang M; Liu X; Wang D; Ruan X; Wang P; Liu L; Xue Y
BMC Cancer; 2023 Mar; 23(1):237. PubMed ID: 36915038
[TBL] [Abstract][Full Text] [Related]
7. Novel Molecular Subtyping Scheme Based on In Silico Analysis of Cuproptosis Regulator Gene Patterns Optimizes Survival Prediction and Treatment of Hepatocellular Carcinoma.
Jiang H; Chen H; Wang Y; Qian Y
J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762710
[TBL] [Abstract][Full Text] [Related]
8. DLAT as a Cuproptosis Promoter and a Molecular Target of Elesclomol in Hepatocellular Carcinoma.
Gao F; Yuan Y; Ding Y; Li PY; Chang Y; He XX
Curr Med Sci; 2023 Jun; 43(3):526-538. PubMed ID: 37286711
[TBL] [Abstract][Full Text] [Related]
9. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a cuproptosis-related signature to evaluate immune features and predict prognosis in colorectal cancer.
Li L; Sun F; Kong F; Feng Y; Song Y; Du Y; Liu F; Kong X
Front Oncol; 2023; 13():1083956. PubMed ID: 37384293
[TBL] [Abstract][Full Text] [Related]
11. Novel insights into anticancer mechanisms of elesclomol: More than a prooxidant drug.
Gao J; Wu X; Huang S; Zhao Z; He W; Song M
Redox Biol; 2023 Nov; 67():102891. PubMed ID: 37734229
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of cuproptosis-related lncRNAs associated with pancreatic cancer immune microenvironment based on single-cell.
Sun Y; Yao L; Man C; Gao Z; He R; Fan Y
Front Immunol; 2023; 14():1220760. PubMed ID: 37822927
[TBL] [Abstract][Full Text] [Related]
13. Molecular Subtyping Based on Cuproptosis-Related Genes and Characterization of Tumor Microenvironment Infiltration in Kidney Renal Clear Cell Carcinoma.
Ji ZH; Ren WZ; Wang HQ; Gao W; Yuan B
Front Oncol; 2022; 12():919083. PubMed ID: 35875087
[TBL] [Abstract][Full Text] [Related]
14. A novel prognostic scoring model based on copper homeostasis and cuproptosis which indicates changes in tumor microenvironment and affects treatment response.
Ma YL; Yang YF; Wang HC; Yang CC; Yan LJ; Ding ZN; Tian BW; Liu H; Xue JS; Han CL; Tan SY; Hong JG; Yan YC; Mao XC; Wang DX; Li T
Front Pharmacol; 2023; 14():1101749. PubMed ID: 36909185
[No Abstract] [Full Text] [Related]
15. Development and validation of cuproptosis molecular subtype-related signature for predicting immune prognostic characterization in gliomas.
Huang H; Lv Z; Yang L; Zhang X; Deng Y; Huang Z; Bi H; Sun X; Zhang M; Hu D; Liang H; Hu F
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11499-11515. PubMed ID: 37392200
[TBL] [Abstract][Full Text] [Related]
16. Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy.
Zheng P; Zhou C; Lu L; Liu B; Ding Y
J Exp Clin Cancer Res; 2022 Sep; 41(1):271. PubMed ID: 36089608
[TBL] [Abstract][Full Text] [Related]
17. Identification of cuproptosis-related subtypes and the development of a prognostic model in glioma.
Wu Z; Li W; Zhu H; Li X; Zhou Y; Chen Q; Huang H; Zhang W; Jiang X; Ren C
Front Genet; 2023; 14():1124439. PubMed ID: 36936439
[No Abstract] [Full Text] [Related]
18. Identification of a prognostic cuproptosis-related signature in hepatocellular carcinoma.
Chen Y; Tang L; Huang W; Abisola FH; Zhang Y; Zhang G; Yao L
Biol Direct; 2023 Feb; 18(1):4. PubMed ID: 36750831
[TBL] [Abstract][Full Text] [Related]
19. A novel cuproptosis-related subtypes and gene signature associates with immunophenotype and predicts prognosis accurately in neuroblastoma.
Tian XM; Xiang B; Yu YH; Li Q; Zhang ZX; Zhanghuang C; Jin LM; Wang JK; Mi T; Chen ML; Liu F; Wei GH
Front Immunol; 2022; 13():999849. PubMed ID: 36211401
[TBL] [Abstract][Full Text] [Related]
20. Identification of a novel prognostic signature composed of 3 cuproptosis-related transcription factors in colon adenocarcinoma.
Zhou L; Zhang Y; Xu Y; Jiang T; Tang L
Genes Genomics; 2023 Aug; 45(8):1047-1061. PubMed ID: 37318704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
